Search Results - S Bringhen

Refine Results
  1. 1

    Age and aging in blood disorders: multiple myeloma by Sonja Zweegman, Antonio Palumbo, Sara Bringhen, Pieter Sonneveld

    Published in Haematologica (2014-07-01)
    Get full text
    Article


  2. 2

    Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update? by Monika Engelhardt, Kwee Yong, Sara Bringhen, Ralph Wäsch

    Published in Haematologica (2019-11-01)
    Get full text
    Article


  3. 3

    In search of the optimal proteosome inhibitor. How, when and for whom? by Monika Engelhardt, Sara Bringhen, Philippe Moreau, Ralph Wäsch, Johannes Waldschmidt

    Published in Haematologica (2021-04-01)
    Get full text
    Article


  4. 4

    Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes by Maria Teresa Petrucci, Sara Bringhen, Cristina Entrala Cerezo, João Mendes, Patrizio Armeni

    Published in Hematology (2024-12-01)
    Get full text
    Article


  5. 5

    The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma by Francesca Bonello, Mariella Grasso, Mattia D’Agostino, Ivana Celeghini, Alessia Castellino, Mario Boccadoro, Sara Bringhen

    Published in Pharmaceuticals (2020-12-01)
    Get full text
    Article


  6. 6

    P164 | REAL-WORLD APPROACHES TO VACCINATION AND ANTIMICROBIAL PROPHYLAXIS IN MULTIPLE MYELOMA: A SURVEY ACROSS EMN CENTERS by O. Annibali, G. Barilà, C. Clissa, D. Vincelli, D. Derudas, B. Rossini, F. Guidotti, S. Bringhen, E. Zamagni, M. Boccadoro, M.T. Petrucci

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  7. 7

    P24: EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE LENALIDOMIDE-SPARING REGIMENS IN EUROPE by M Mateos, X Leleu, E Zamagni, M Delforge, S Bringhen, A Broijl, J de la Rubia, A Shaw, A Brescianini, S Gonzalez-McQuire, S Patel, P Moreau

    Published in HemaSphere (2022-04-01)
    Get full text
    Article


  8. 8

    Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients by Enrique M. Ocio, Sara Bringhen, Joaquin Martinez-Lopez, Jesus San-Miguel, Stefania Oliva, Paula Rodriguez-Otero, Nadia Le Roux, Yvonne Dong, Severine Doroumian, Sandrine Macé, Maria-Victoria Mateos

    Published in HemaSphere (2023-02-01)
    Get full text
    Article


  9. 9

    30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis by Enrique M. Ocio, Aurore Perrot, Philippe Moreau, Maria‐Victoria Mateos, Sara Bringhen, Joaquín Martínez‐López, Lionel Karlin, Song‐Yau Wang, Corina Oprea, Yi Li, Ercem Kodas, Jesus San‐Miguel

    Published in HemaSphere (2024-11-01)
    Get full text
    Article


  10. 10

    P183 | DELAYED DARATUMUMAB ADDITION TO LENALIDOMIDE-DEXAMETHASONE IN OLDER MULTIPLE MYELOMA PATIENTS: INSIGHTS FROM REAL-WORLD DATA by L. Cani, A. Di Nicola, A. Evangelista, I. Delle Donne, G. Bertuglia, A. Casson, M. D’agostino, F. Gay, A. Larocca, E. Marchetti, R. Mina, S. Oliva, T. Picardi, B. Bruno, S. Bringhen, G. Benevolo

    Published in Haematologica (2025-09-01)
    Get full text
    Article


  11. 11

    Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies by Simona Caltagirone, Marina Ruggeri, Simona Aschero, Milena Gilestro, Daniela Oddolo, Francesca Gay, Sara Bringhen, Caterina Musolino, Luca Baldini, Pellegrino Musto, Maria T. Petrucci, Gianluca Gaidano, Roberto Passera, Benedetto Bruno, Antonio Palumbo, Mario Boccadoro, Paola Omedè

    Published in Haematologica (2014-10-01)
    Get full text
    Article


  12. 12

    The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review by Hira Mian, Arleigh McCurdy, Smith Giri, Shakira Grant, Bram Rochwerg, Erica Winks, Ashley E. Rosko, Monika Engelhardt, Charlotte Pawlyn, Gordon Cook, Graham Jackson, Sara Bringhen, Thierry Facon, Alessandra Larocca, Sonja Zweegman, Tanya M. Wildes

    Published in Blood Cancer Journal (2023-01-01)
    Get full text
    Article


  13. 13

    Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial by Antonio Palumbo, Alessandra Larocca, Mariella Genuardi, Katarzyna Kotwica, Francesca Gay, Davide Rossi, Giulia Benevolo, Valeria Magarotto, Federica Cavallo, Sara Bringhen, Cecilia Rus, Luciano Masini, Massimo Iacobelli, Gianluca Gaidano, Constantine Mitsiades, Kenneth Anderson, Mario Boccadoro, Paul Richardson

    Published in Haematologica (2010-07-01)
    Get full text
    Article


  14. 14

    Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis by Fredrik Schjesvold, Paul G. Richardson, Thierry Facon, Adrián Alegre, Andrew Spencer, Artur Jurczyszyn, Kazutaka Sunami, Laurent Frenzel, Chang-Ki Min, Sophie Guillonneau, Peggy L. Lin, Solenn Le-Guennec, Frank Campana, Helgi van de Velde, Samira Bensfia, Sara Bringhen

    Published in Haematologica (2022-03-01)
    Get full text
    Article


  15. 15

    Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma by Francesca Bonello, Serena Rocchi, Serena Rocchi, Gregorio Barilà, Michela Sandrone, Marco Talarico, Marco Talarico, Elena Zamagni, Elena Zamagni, Matilde Scaldaferri, Susanna Vedovato, Cecilia Bertiond, Laura Pavan, Sara Bringhen, Francesco Cattel, Renato Zambello, Michele Cavo, Michele Cavo, Roberto Mina

    Published in Frontiers in Oncology (2022-03-01)
    Get full text
    Article


  16. 16

    Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis by Fredrik H. Schjesvold, Paul G. Richardson, Thierry Facon, Adrián Alegre, Andrew Spencer, Artur Jurczyszyn, Kazutaka Sunami, Laurent Frenzel, Chang-Ki Min, Sophie Guillonneau, Peggy L. Lin, Solenn Le-Guennec, Frank Campana, Helgi van de Velde, Samira Bensfia, Sara Bringhen

    Published in Haematologica (2020-06-01)
    Get full text
    Article


  17. 17

    Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies by Sara Bringhen, Roberto Mina, Maria Teresa Petrucci, Gianluca Gaidano, Stelvio Ballanti, Pellegrino Musto, Massimo Offidani, Stefano Spada, Giulia Benevolo, Elena Ponticelli, Piero Galieni, Michele Cavo, Tommaso Caravita Di Toritto, Francesco Di Raimondo, Vittorio Montefusco, Antonio Palumbo, Mario Boccadoro, Alessandra Larocca

    Published in Haematologica (2019-08-01)
    Get full text
    Article


  18. 18

    Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-do... by María-Victoria Mateos, Sara Bringhen, Paul G. Richardson, Juan Jose Lahuerta, Alessandra Larocca, Albert Oriol, Mario Boccadoro, Ramón García-Sanz, Francesco Di Raimondo, Dixie-Lee Esseltine, Helgi van de Velde, Avinash Desai, Anil Londhe, Jesús F. San Miguel, Antonio Palumbo

    Published in Haematologica (2014-06-01)
    Get full text
    Article


  19. 19

    Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)... by Sara Bringhen, Alberto Milan, Claudio Ferri, Ralph Wäsch, Francesca Gay, Alessandra Larocca, Marco Salvini, Evangelos Terpos, Hartmut Goldschmidt, Michele Cavo, Maria Teresa Petrucci, Heinz Ludwig, Holger W. Auner, Jo Caers, Martin Gramatzki, Mario Boccadoro, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt

    Published in Haematologica (2018-09-01)
    Get full text
    Article


  20. 20

    Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies by Roberto Mina, Francesca Bonello, Maria Teresa Petrucci, Anna Marina Liberati, Concetta Conticello, Stelvio Ballanti, Pellegrino Musto, Attilio Olivieri, Giulia Benevolo, Andrea Capra, Milena Gilestro, Piero Galieni, Michele Cavo, Agostina Siniscalchi, Antonio Palumbo, Vittorio Montefusco, Gianluca Gaidano, Paola Omedé, Mario Boccadoro, Sara Bringhen

    Published in Haematologica (2020-02-01)
    Get full text
    Article


Search Tools: